NCT03450057 · REGISTRY CONDITION SEARCH

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2024-03-29

The purpose of this study was to evaluate the effects of daratumumab with dexamethasone (DaraD) in subjects with relapsed or refractory multiple myeloma and renal impairment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

The Evaluation of Progression Free Survival (PFS) in Subjects With Relapsed or Refractory Multiple Myeloma and Renal Impairment Treated With Daratumumab and Dexamethasone.

→

outcome · POSTED

Overall Response Rate (ORR)

→

outcome · POSTED

Renal Response Rate (RRR)

→

outcome · POSTED

Duration of Response in Patients With RI

→

outcome · POSTED

Time to Next Therapy

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

To Assess the Safety and Tolerability of Daratumumab With Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma (RRMM) and Renal Impairment (RI).

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Males and females at least 18 years of age. 2. Voluntary written informed consent before performance of any study-related procedure. 3. Subject must have documented multiple myeloma as defined by the criteria below: Monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma. AND any or more of the following myeloma defining events: * Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: * Hypercalcaemia: serum calcium \>0.25 mmol/L (\>1 mg/dL) higher than the upper limit of normal or \>2.75 mmol/L (\>11 mg/dL) * Renal insufficiency: creatinine clearance \<40 mL per min or serum creatinine \>177 μmol/L (\>2 mg/dL) * Anaemia: haemoglobin value of \>20 g/L below the lower limit of normal, or a haemoglobin value \<100 g/L * Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PETCT * Any one or more of the following biomarkers of malignancy: * Clonal bone marrow plasma cell percentage ≥60% * Involved:uninvolved serum free light chain ratio ≥100 * \>1 focal lesions on MRI studies 4. Prior treatment with at least two lines of treatment that included both bortezomib- and lenalidomide based regimens. 5. Documented evidence of progressive disease (PD) as defined by the modified IMWG criteria on or after the last regimen if the patient responded to previous regimens. 6. Subjects must have measurable disease as defined by any of the following: * Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL (except for IgA subtype: ≥ 0.5 g/dL) or urine M-protein level ≥ 200 mg/24 hours; or * Light chain multiple myeloma: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free-light-chain ratio. 7. Renal impairment defined as eGFR \< 30 ml/min/1.73 m2 (calculated with the CKD-EPI formula) or in need for dialysis. Patients who undergo intraperitoneal dialysis may also be included. 8. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2. 9. Willingness and ability to participate in study procedures. 10. Reproductive Status 1. Women of childbearing potential (WOCBP) must have two negative serum or urine pregnancy tests, one 10-14 days prior to start of the study drug and one within 24 hours prior to the start of study drug. Females are not of reproductive potential if they have been in natural menopause for at least 24 consecutive months, or have had a hysterectomy and/or bilateral oophorectomy. 2. Women must not be breastfeeding. 3. WOCBP must agree to follow instructions for methods of contraception for 4 weeks before the start of treatment with study drugs, for the duration of treatment with study drugs, and for 3 months after cessation of study treatment. 4. Males who are sexually active must always use a latex or synthetic condom during any sexual contact with females of reproductive potential, even if they have undergone a successful vasectomy. They must also agree to follow instructions for methods of contraception for 4 weeks before the start of treatment with study drugs, for the duration of treatment with study drugs, and for a total of 3 months post-treatment completion. 5. Male patients must not donate sperm for up to 90 days post treatment completion. 6. Female patients must not donate eggs for up to 90 days post treatment completion. 7. Azoospermic males and WOCBP who are not heterosexually active are exempt from contraceptive requirements. However, WOCBP will still undergo pregnancy testing as described in this section. Exclusion Criteria: 1. Previous therapy with daratumumab or other anti-CD38 therapy. 2. Anti-myeloma treatment within 2 weeks prior to Cycle 1, Day 1. 3. Cumulative dose of corticosteroids greater than or equal to the equivalent of 140mg prednisone for ≥ 4 days or a dose of corticosteroids greater than or equal to the equivalent of 40 mg/day of dexamethasone for ≥ 4 days within the 2-week period prior to Cycle 1, Day 1. 4. Previous allogenic stem cell transplant; or Autologous Stem Cell Transplantation (ASCT) within 12 weeks before Cycle 1, Day 1. 5. Clinical signs of meningeal involvement of multiple myeloma. 6. Subject has either of the following: 1. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal. 2. Known moderate or severe persistent asthma (see Appendix 7), within 2 years from C1D1, or currently has uncontrolled asthma of any classification. Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study. 7. Clinically significant cardiac disease, including: 1. Myocardial infarction within 1 year, or unstable or uncontrolled condition (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV). 2. Uncontrolled cardiac arrhythmia (CTCAE Grade 2 or higher) (atrial fibrillation with controlled ventricular rate is allowed) or clinically significant ECG abnormalities. 3. ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) \>470 msec. 8. Any of the following: 1. Known active hepatitis A 2. Patient is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \[HBsAg\]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \[anti-HBc\] and/or antibodies to hepatitis B surface antigen \[anti-HBs\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR. 3. Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response \[SVR\], defined as aviremia at least 12 weeks after completion of antiviral therapy). 9. Known to be seropositive for human immunodeficiency virus (HIV). 10. Amyloidosis, or any prior or concurrent malignancy, except for the following: 1. Adequately treated basal cell or squamous cell skin cancer. 2. Any cancer (other than in-situ) from which the subject has been disease-free for 3 years prior to study entry. 11. Any of the following laboratory test results during screening: 1. Absolute neutrophil count ≤ 1.0 × 10\^9/L; 2. Hemoglobin level ≤ 7.5 g/dL (≤ 4.65 mmol/L); 3. Platelet count \< 75 × 10\^9/L in patients in whom \< 50% of bone marrow nucleated cells are plasma cells and \< 50x10\^9/L in patients in whom more than 50% of bone marrow nucleated cells are plasma cells; 4. Alanine aminotransferase level ≥ 2.5 times the upper limit of normal (ULN); 12. Pregnant or nursing women.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Dexamethasone was administered according to the standard recommended dose of 40 mg (20 mg for patients \> 75 years of age) orally once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
intervention Names
Drug: Daratumumab with dexamethasone
label
Single arm trial receiving daratumumab with dexamethasone (DaraD)
type
EXPERIMENTAL

interventions

arm Group Labels
Single arm trial receiving daratumumab with dexamethasone (DaraD)
description
Daratumumab: Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs). Dexamethasone: Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
name
Daratumumab with dexamethasone
other Names
DaraD
Darzalex
Dara
Dex
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

intervention Model Description

Single arm: Daratumumab and Dexamethasone

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 38
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Progression free survival was defined as the time, in months, from treatment initiation (C1D1) to the date of the first documented disease progression or death due to any cause, whichever came first. Clinical deterioration was not considered progression. For patients who neither progressed nor died, the survival time was censored at the date of their last disease assessment. For patients who started a new anti-tumor treatment, survival time was censored at the date of the start of the new treatment.
measure
The Evaluation of Progression Free Survival (PFS) in Subjects With Relapsed or Refractory Multiple Myeloma and Renal Impairment Treated With Daratumumab and Dexamethasone.
time Frame
Duration from first daratumumab administration until death or last assessment, months.

secondary Outcomes

description
Overall response rate was defined as the proportion of subjects who achieve a best response of PR or better using modified IMWG criteria as their best overall response.
measure
Overall Response Rate (ORR)
time Frame
From first dose of Daratumumab until end of treatment, PD or death (approximately up to 30 months)
description
Renal response rate was defined as the proportion of enrolled subjects who achieve a best response of renal partial response (PRRenal) or better using the IMWG criteria.
measure
Renal Response Rate (RRR)
time Frame
From first dose of Daratumumab until end of treatment, PD or death (approximately up to 30 months )
description
Duration of response was restricted to the subjects that achieve a best objective response of PR or better. It was measured from the time, in months, that the criteria for objective response are first met until the date of a progression event (according to the primary definition of PFS).
measure
Duration of Response in Patients With RI
time Frame
Assessed monthly from first dose of Daratumumab until PD or death from any cause (approximately up to 30 months)
description
Time to next therapy was defined as the time, in months, from Cycle 1 Day 1 to the date to next anti-neoplastic therapy or death from any cause, whichever comes first.
measure
Time to Next Therapy
time Frame
From first dose until the date to next anti-neoplastic therapy or death from any cause, whichever comes first (approximately up to 30 months)
description
Overall survival was defined as the time, in months, from the first dose of therapy to the date of death from any cause.
measure
Overall Survival
time Frame
Time from first dose of study treatment to death (approximately up to 30 months)
description
The incidence of Adverse Events and Treatment Emergent Adverse Events in patients with refractory and relapsed multiple myeloma and renal impairment treated with daratumumab with dexamethasone was assessed according to the common Terminology Criteria for Adverse Events.
measure
To Assess the Safety and Tolerability of Daratumumab With Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma (RRMM) and Renal Impairment (RI).
time Frame
Continuously throughout the study, starting from informed consent until 30 days after last study treatment (approximately up to 30 months).

Full study description

brief Summary: The purpose of this study was to evaluate the effects of daratumumab with dexamethasone (DaraD) in subjects with relapsed or refractory multiple myeloma and renal impairment.
detailed Description: This was a multicenter, single arm, open-label phase 2 study. 38 subjects were enrolled to receive daratumumab and dexamethasone. Treatment cycles had a duration of 28 days. Subjects received treatment until either disease progression, death, unacceptable toxicity or for a maximum of 30 months. Drug administration and follow-up visits occurred more frequently for early cycles (weekly for the first 8 weeks, every two weeks for weeks 9-24 and then every 4 weeks). Disease evaluations occurred monthly and involved mainly measurements of myeloma proteins. Other assessments included bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin, and β2- microglobulin and albumin.

Source references

references

citation
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study. Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21. No abstract available.
pmid
37340832
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-0d40220bdc66d010dc05
requested nct id
NCT03450057
primary nct id
NCT03450057
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
07a508df07d320a6f51bb8dd86eae699e8be3e72c842ff0dc45d1cd0d5c84482
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-0d40220bdc66d010dc05
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03450057
occurrences
context exact
NCT03450057
end
11
exact text
NCT03450057
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/998/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f7c7d531c2f958f1b3b6b12bb952be3a58dc7cb618064db7e1dca889463ca7b4
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice